iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. (ITOS) Revenue
Annual & quarterly revenue history · segment & region breakdown
ITOS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsiTeos Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 177.89% year-over-year from $0.04B in FY2024.
Revenue trend
2024 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.04B | +$0.02B | +177.89% |
| 2023-12-31 | $0.01B | -$0.26B | -95.29% |
| 2022-12-31 | $0.27B | -$0.08B | -22.38% |
| 2021-12-31 | $0.34B | +$0.34B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income iTeos Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
iTeos Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from iTeos Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ITOS revenue · 4 questionsITOS's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 177.89% year-over-year from $0.04B in FY2024.
▸ Source: FMP · iTeos Therapeutics, Inc. SEC filings · GAAP · iTeos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026